Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Samsara Inc (IOT) vs Smith & Nephew plc (SNN) Price & Performance

Samsara IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Samsara Inc vs Smith & Nephew plc — how do they compare? Samsara Inc trades at $41.5 (market cap $23.72B), while Smith & Nephew plc trades at $27.21 (market cap $11.31B). The key difference: Samsara Inc is far larger — about 2.1× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Samsara Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Samsara Inc for 19 Days and Smith & Nephew plc for 120 Days on average.

IOTSNN
Market Cap
$23.72B$11.31B
Volume
4,096,6831,050,005
Sector
TechnologyHealth
52-Week High
$45.22$37.17
52-Week Low
$24.25$26.42
Typical Hold Time
19 Days120 Days
Enterprise Value
$22.96B$14.35B
Dividend Yield
—2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Samsara Inc

Samsara Inc. (IOT) trades at $40.51, down 2.95% on the day, but maintains a bullish technical outlook with strong analyst support. The company reported robust Q2 2027 results, beating earnings estimates with $0.20 EPS versus $0.16 expected, and achieved 30% year-over-year revenue growth. Recent partnerships and product launches, like the Laval Rocket sponsorship and Samsara MCP, highlight ongoing business expansion.

The stock offers upside to the $51.15 consensus price target, driven by solid fundamentals and institutional accumulation. However, elevated valuation multiples (P/E 270.07, P/S 12.79) and negative net income in 2025 pose risks if growth moderates. Positive cash flow trends and a 75% buy rating from analysts support a constructive outlook, though investors should monitor competitive pressures and execution on profitability goals.

Smith & Nephew plc

SNN trades at $26.96, near its 52-week low, with a bearish technical signal. The company has shown improving fundamentals, with revenue growing from $5.2B in 2022 to $6.16B in 2025 and net income margin expanding to 10.08%. Recent product launches, like the EVOS PELVIC System, highlight innovation, but the stock faces negative sentiment from analyst downgrades and CFO departure news.

The outlook is mixed: strong profitability and cash flow support value, but bearish technicals and cautious analyst consensus (26% buy, 65% hold) suggest limited near-term upside. Key risks include execution challenges and competitive pressures. Investors should weigh solid fundamentals against weak market sentiment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Samsara Inc

Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.

Read more on IOT →

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN →